Hims & Hers Health Inc. (NYSE:HIMS) is a leading telehealth company that has recently announced a significant partnership with Novo Nordisk (NYSE:NVO) to offer weight-loss medications on its platform. This collaboration not only resolves a previous legal dispute but also marks a strategic shift for HIMS, enhancing its healthcare solutions portfolio. With a focus on accessible healthcare, Hims & Hers competes with other telehealth giants like Teladoc Health and Amwell. On March 9, 2026, BTIG reiterated its Neutral rating for HIMS, maintaining a hold action, with the stock priced at $21.87, as reported by StreetInsider.
The partnership with Novo Nordisk allows Hims & Hers to provide U.S. customers access to FDA-approved GLP-1 treatments, including semaglutide injections and tablets. This move is expected to significantly impact the U.S. weight loss market, offering more affordable and flexible dosing options for consumers. The stock for HIMS has seen a notable increase to $21.95, up 39.45%, with fluctuations between $20.99 and $23.51 during the day. Over the past year, HIMS reached a high of $70.43 and a low of $13.74. The company's market capitalization stands at approximately $4.82 billion, with a trading volume of 109.37 million shares.
Hims & Hers will continue to offer compounded semaglutide on a limited basis, only when clinically necessary, and will cease the promotion of compounded GLP-1s in its marketing materials. CEO Andrew Dudum expressed enthusiasm about the partnership, highlighting the evolving U.S. weight loss landscape with more affordable, FDA-approved medications and flexible dosing options.
